Delving into the Latest Updates on Tepotinib Hydrochloride Hydrate with Synapse

RegulationPriority Review (US), Accelerated Approval (US), Orphan Drug (JP), Orphan Drug (KR), Orphan Drug (AU), Fast Track (JP), Special Review Project (CN), Breakthrough Therapy (US), Orphan Drug (US)

Login to view timeline

Structure

Molecular FormulaC29H31ClN6O3

InChIKeyKZVOMLRKFJUTLK-UHFFFAOYSA-N

CAS Registry1946826-82-9

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal MET protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving tepotinib with ramucirumab may lower the chance of the cancer from growing or spreading in patients with stage IV or recurrent non-small cell lung cancer.

Start Date08 Aug 2024

Sponsor / Collaborator

Eli Lilly & Co.

[+2]

NCT06083857 / RecruitingPhase 1/2IIT

An Open-Label Phase I/II Study to Evaluate the Safety and prelimiBasnary Efficacy of Amivantamab and Tepotinib Combination in MET-altered Non-small Cell Lung Cancer (NSCLC)

To learn if the combination of amivantamab and tepotinib can help to control NSCLC. The safety of this drug combination will also be studied.

Start Date18 Jun 2024

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

NCT06106802 / Not yet recruitingPhase 2IIT

Lazertinib and Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment: A Phase II Multi-center Trial

As the 3rd generation, EGFR TKI has become a standard treatment option for the 1st line therapy in EGFR mutated patients, the necessity for evaluating resistant mechanism to determine the matched subsequent therapeutic option has been highlighted. From the 1st line Osimertinib treatment, the heterogenous resistance mechanism has been observed showing most commonly by MET amplification (7-15%) followed by additional on-target EGFR mutation (6-10%), BRAF, PI3KCA, KRAS, HER2 mutation (13-14%) and still 40 to 50% remain unknown for the mechanism. (A. Leonetti et al.British Journal of Cancer(2019))
Based on the observation showing the MET amplification as the most common resistance mechanism to the 3rd generation EGFR TKI treatment, the "TATTON" study, a multi-arm, phase IB trial, demonstrated early clinical data of Osimertinib in combined with savolitinib. Among the patients, c-MET amplified patients who were previously treated with 3rd generation EGFR TKI, a combination of Osimertinib and savolitinib, showed an objective response rate of 33% and median PFS of 5.5 months. (G. Oxnard et al. Annals of Oncology(2020))
The clinical efficacy of Osimertinib with savolitinib in MET overexpressed or amplification patients are reported from the global phase II, "SAVANNAH" study. The preliminary results from the SAVANNAH trial showed that Osimertinib plus savolitinib demonstrated an objective response rate of 49% in patients with a high level of MET overexpression and/or amplification, defined as IHC90+ and/or FISH 10+, whose disease progressed on treatment with Osimertinib. The highest ORR was observed in patients with a high level of MET who were not treated with prior chemotherapy (52%). In patients whose tumors did not show a high level of MET, the ORR was 9% (MJ Ahn, WCLC, 2022). There are ongoing global Phase III SAFFRON study to validate the outcome from SAVANNAH study.
It has been reported that around 62% of tumor in Osimertinib progressed sample has MET overexpression and/or amplification, and more than one-third (34%) met the defined high MET level cut-off.
As Lazertinib is about to be approved as the treatment option for the treatment naïve EGFR mutated NSCLC, it is also becoming important to develop a further treatment plan based on the MET amplification status. In this study, the investigators designed a phase II study based on the MET amplification status to evaluate the clinical efficacy of Lazertinib + tepotinib.

Start Date02 Feb 2024

Sponsor / Collaborator

Samsung Medical Center

100 Clinical Results associated with Tepotinib Hydrochloride Hydrate

Login to view more data

100 Translational Medicine associated with Tepotinib Hydrochloride Hydrate

Login to view more data

100 Patents (Medical) associated with Tepotinib Hydrochloride Hydrate

Login to view more data

177

Literatures (Medical) associated with Tepotinib Hydrochloride Hydrate

01 Jan 2025·INTERNAL MEDICINE

Kidney Injury in Patient with Non-small-cell Lung Cancer Receiving Tepotinib

Article

Author: Mitani, Reo ; Oda, Naohiro ; Takata, Ichiro ; Tokura, Takehiko ; Onishi, Akifumi

We herein report a 68-year-old man with advanced non-small-cell lung cancer treated with tepotinib who showed marked general edema, hypoalbuminemia, and an elevated serum creatinine level. Although tepotinib-induced kidney injury due to creatinine transporter inhibition has been reported, renal biopsy findings suggested tubulointerstitial injury due to decreased renal blood flow, likely secondary to refractory fluid retention. This case highlights the potential for true kidney injury during tepotinib therapy and underscores the importance of careful monitoring and management of adverse renal effects.

06 Dec 2024·ONCOLOGIST

Exceptional sustained long-term complete response to Tepotinib in a MET-amplified advanced intrahepatic biliary tract cancer failing Durvalumab plus Cisplatin and Gemcitabine

Article

Author: Doleschal, Bernhard ; Kerschner, Paul ; Burghofer, Jonathan ; Reichinger, Andreas ; Rumpold, Holger ; Webersinke, Gerald ; Essl, Leo

Abstract:

Background:

Biliary tract cancers (BTCs) are a diverse group of malignancies with varied genetic backgrounds. The prevalence of intrahepatic cholangiocarcinoma (iCC) is increasing, particularly in Western countries. Despite advancements in treatments, the prognosis for BTC remains poor. Recent molecular profiling has revealed that up to 40% of iCC cases have targetable genetic alterations. MET amplification, although rare, presents a significant target for therapy.

Case Presentation:

A 25-year-old female with a history of ulcerative colitis presented with shoulder pain and a positron emission tomography–computed tomography (PET–CT) scan revealed an enlarged liver and multiple metastases. Histopathological analysis diagnosed poorly differentiated adenocarcinoma. First-line therapy with Cisplatin, Gemcitabine, and Durvalumab resulted in disease progression. Molecular profiling identified a TP53 mutation and MET amplification. Based on these findings, Tepotinib was initiated. Tepotinib treatment led to a significant reduction in tumor size and normalization of CA 19-9 levels within 2 months, achieving a complete metabolic remission lasting up to 17 months. The treatment was well tolerated with minimal side effects.

Discussion:

MET-amplified BTCs are exceedingly rare, and evidence for targeted treatment is limited. This case demonstrates the efficacy of Tepotinib in a young patient with MET-amplified iCC, showing a long-term response and suggesting a potential new standard treatment option for this molecularly defined entity. This case also highlights the aggressive nature of MET-amplified tumors and the need for targeted second-line therapies.

Conclusion:

Tepotinib showed remarkable efficacy in treating MET-amplified intrahepatic cholangiocarcinoma, underscoring the importance of molecular profiling in BTCs and suggesting a potential new therapeutic approach for this rare cancer subtype.

01 Nov 2024·Thoracic Cancer

Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report

Article

Author: Liu, Xiaoyan ; Zhao, Jing ; Chen, Minjiang ; Gao, Xiaoxing ; Li, Rongzhen ; Zhong, Wei ; Wang, Mengzhao ; Xu, Yan

Abstract:

Mesenchymal–epithelial transition (MET) exon 14 (METex14) skipping mutation is a rare (3%–4%) driver mutation in non‐small cell lung cancer (NSCLC). Tepotinib, a selective MET inhibitor, has shown promise in treating METex14 skipping‐mutated NSCLC. However, its feasibility for perioperative application remains unclear. This report describes a 60‐year‐old man with stage IIIA (cT2N2M0) lung adenocarcinoma harboring a METex14 skipping mutation. After initial treatment with savolitinib was discontinued due to grade 4 transaminitis, the patient was switched to tepotinib, resulting in significant tumor regression. Six months later, further shrinkage was observed, and surgery revealed remarkable pathological response with no residual tumor in lymph nodes (ypT2N0M0, IB). Postoperative tepotinib continued, with no relapse at 6‐month follow‐up. This case highlights the potential of tepotinib as neoadjuvant therapy for resectable METex14 skipping‐mutated NSCLC, warranting further clinical trials.

22

News (Medical) associated with Tepotinib Hydrochloride Hydrate

18 Nov 2024

·www.businesswire.com

U.S. Food and Drug Administration Approves FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® (tepotinib) to Identify Patients with MET Exon 14 Skipping Alterations in Non-Small Cell Lung Cancer

BOSTON--( BUSINESS WIRE )-- Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne ® Liquid CDx to be used as a companion diagnostic for TEPMETKO ® (tepotinib) developed by EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada. TEPMETKO received accelerated approval from the FDA in February 2021 and traditional approval in February 2024 for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition ( MET ) exon 14 skipping alterations ( MET ex14). 1 FoundationOne Liquid CDx is the first FDA-approved companion diagnostic to identify patients who may be eligible for TEPMETKO. NSCLC accounts for approximately 85% of lung cancers, 2 of which 3-4% are associated with MET ex14. 3 MET ex14 skipping alterations in patients have been associated with advanced disease and a poor prognosis. 4 “Access to a high-quality liquid biopsy, like FoundationOne Liquid CDx, can help unlock the power of precision medicine for more patients with non-small cell lung cancer,” said Mia Levy, M.D., Ph.D., chief medical officer at Foundation Medicine. “We’re proud that our liquid biopsy is the first companion diagnostic approved in the U.S. for TEPMETKO as it will help identify more patients with MET ex14 skipping alterations who may be appropriate for targeted treatment.” Foundation Medicine is the only company with an FDA-approved portfolio of tissue and blood-based comprehensive genomic profiling tests. From a routine blood sample, FoundationOne Liquid CDx analyzes more than 300 cancer-related genes to provide genomic insights. With today’s approval, Foundation Medicine has more than 19 FDA-approved companion diagnostic indications for NSCLC, the most of any company. 5 “Targeted therapies have led a revolution to how lung cancer is treated,” said GO2 for Lung Cancer President and CEO Laurie Ambrose. “Biomarker testing plays a crucial part in getting these treatments into the hands of patients. We’re excited to see that patients with advanced NSCLC have more access to treatment options because of non-invasive liquid biopsies.” Foundation Medicine is the global leader in approved companion diagnostic indications, with 50% of all approved companion diagnostic indications for next-generation sequencing (NGS) testing in the United States and Japan. 6 Foundation Medicine ® and FoundationOne ® are registered trademarks of Foundation Medicine, Inc. About Foundation Medicine: Your Essential Partner in Cancer Care Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit us on www.FoundationMedicine.com and follow us on LinkedIn and X . About FoundationOne ® Liquid CDx FoundationOne ® Liquid CDx is a qualitative next generation sequencing based in vitro diagnostic test for prescription use only that uses targeted high throughput hybridization-based capture technology to analyze 324 genes utilizing circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood of advanced cancer patients. The test is FDA-approved to report short variants in over 300 genes and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and genomic alteration status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com . ____________________ 1 TEPMETKO. Prescribing Information. EMD Serono; 2024. Accessed May 24, 2024. https://www.emdserono.com/us-en/pi/tepmetko-pi.pdf 2 American Cancer Society. Key Statistics for Lung Cancer. Updated January 29, 2024. Accessed May 22, 2024. https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html 3 The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature . 2014;511:543-550. https://doi-org.libproxy1.nus.edu.sg/10.1038/nature13385 4 Awad MM, Leonardi GC, Kravets S, et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer . 2019;133:96-102. https://doi-org.libproxy1.nus.edu.sg/10.1016/j.lungcan.2019.05.011 5 Data on File, Foundation Medicine, Inc. 2024 6 Data on File, Foundation Medicine, Inc. 2024

Drug Approval

09 Aug 2024

·www.fda.gov

FDA approves tepotinib for metastatic non-small cell lung cancer

FDA approves tepotinib for metastatic non-small cell lung cancer On February 15, 2024, the Food and Drug Administration granted traditional approval to tepotinib (Tepmetko, EMD Serono, Inc.) for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. View full prescribing information for Tepmetko. Tepotinib was previously granted accelerated approval for this indication on February 3, 2021, based on initial overall response rate (ORR) and duration of response (DOR) in the VISION trial (NCT02864992), a multicenter, non-randomized, open-label, multicohort study. The conversion to traditional approval was based on an additional 161 patients and an added 28 months of follow-up time to assess DOR. Efficacy was demonstrated in a total of 313 patients with metastatic NSCLC harboring MET exon skipping alterations. Patients received tepotinib 450 mg once daily until disease progression or unacceptable toxicity. The primary efficacy measures were ORR and DOR, determined by a Blinded Independent Review Committee. Among 164 treatment-naïve patients, ORR was 57% (95% CI: 49, 65), with 40% of responders having a DOR ≥12 months. Among 149 previously treated patients, ORR was 45% (95% CI: 37, 53), with 36% of responders having a DOR ≥12 months. The most common adverse reactions (≥20%) were edema, nausea, fatigue, musculoskeletal pain, diarrhea, dyspnea, decreased appetite, and rash. The recommended tepotinib dose is 450 mg orally once daily with food. This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. This application was granted breakthrough designation and orphan drug designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. Follow the Oncology Center of Excellence on X (formerly Twitter) @FDAOncologyExternal Link Disclaimer.

Drug ApprovalOrphan DrugAccelerated ApprovalClinical ResultBreakthrough Therapy

09 Aug 2024

·www.fda.gov

FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer

On February 3, 2021, the Food and Drug Administration granted accelerated approval to tepotinib (Tepmetko, EMD Serono Inc.) for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. Efficacy was demonstrated in the VISION trial (NCT02864992), a multicenter, non-randomized, open-label, multicohort study enrolling 152 patients with advanced or metastatic NSCLC with MET exon 14 skipping alterations. Patients received tepotinib 450 mg orally once daily until disease progression or unacceptable toxicity. The main efficacy outcome measures were overall response rate (ORR) determined by a blinded independent review committee using RECIST 1.1 and response duration. Among the 69 treatment naïve patients, the ORR was 43% (95% CI: 32%, 56%) with a median response duration of 10.8 months (95% CI: 6.9, not estimable). Among the 83 previously treated patients, the ORR was 43% (95% CI: 33%, 55%) with a median response duration of 11.1 months (95% CI: 9.5, 18.5). The most common adverse reactions (≥ 20% of patients) were edema, fatigue, nausea, diarrhea, musculoskeletal pain, and dyspnea. Tepotinib can also cause interstitial lung disease, hepatotoxicity, and embryo-fetal toxicity. The recommended tepotinib dose is 450 mg orally once daily with food. View full prescribing information for Tepmetko. This indication is approved under accelerated approval based on overall response rate and response duration. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. This review used the Real-Time Oncology Review, which streamlined data submission prior to the filing of the entire clinical application. The review also used the Oncology Center of Excellence Assessment Aid and the Product Quality Assessment Aid (PQAA), voluntary submissions from the applicant to facilitate the FDA’s assessment. This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this application, a modified Project Orbis was undertaken because of the timing of submission to other regulatory agencies. FDA collaborated with Health Canada, Therapeutic Goods Administration (Australia), and Swissmedic on this review. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. For information on the COVID-19 pandemic, see the following resources: FDA: Coronavirus Disease 2019 (COVID-19) NCI: Coronavirus: What People With Cancer Should Know CDC: Coronavirus (COVID-19) Follow the Oncology Center of Excellence on Twitter @FDAOncologyExternal Link Disclaimer.

Accelerated ApprovalDrug Approval

100 Deals associated with Tepotinib Hydrochloride Hydrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XE	DB15133

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer	KR	Merck & Co., Inc.	23 Nov 2021
Non-Small Cell Lung Cancer	US	EMD Serono, Inc.	03 Feb 2021
c-Met positive non-small cell lung cancer	JP	Merck KGaA	25 Mar 2020

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
RAS/BRAF Wild Type Colorectal Cancer	Phase 2	US	EMD Serono Research & Development Institute, Inc.	28 Jan 2021
RAS/BRAF Wild Type Colorectal Cancer	Phase 2	BE	EMD Serono Research & Development Institute, Inc.	28 Jan 2021
RAS/BRAF Wild Type Colorectal Cancer	Phase 2	CZ	EMD Serono Research & Development Institute, Inc.	28 Jan 2021
RAS/BRAF Wild Type Colorectal Cancer	Phase 2	FR	EMD Serono Research & Development Institute, Inc.	28 Jan 2021
RAS/BRAF Wild Type Colorectal Cancer	Phase 2	IT	EMD Serono Research & Development Institute, Inc.	28 Jan 2021
RAS/BRAF Wild Type Colorectal Cancer	Phase 2	RU	EMD Serono Research & Development Institute, Inc.	28 Jan 2021
RAS/BRAF Wild Type Colorectal Cancer	Phase 2	ES	EMD Serono Research & Development Institute, Inc.	28 Jan 2021
RAS/BRAF Wild Type Colorectal Cancer	Phase 2	GB	EMD Serono Research & Development Institute, Inc.	28 Jan 2021
Neoplasm Metastasis	Phase 2	KR	Merck KGaA	16 Jan 2020
Solid tumor	Phase 2	KR	Merck KGaA	16 Jan 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03940703 (INSIGHT 2, Pubmed) Manual	Phase 2	Non-Small Cell Lung Cancer Second line EGFR Mutation \| MET Amplification	128	Tepotinib plus osimertinib (progression on first-line osimertinib)	tzwbufkdar(cqaukphkwb) = yvjexisuox hwcnpcbxsv (lqveznqwik, 39.7 - 60.3) View more	Positive	25 Aug 2024
NCT03546608 (CTgov)	Phase 1	Hepatic Insufficiency	18	Tepotinib (Healthy Participants (Control))	pjkxktqsmc(slplywxlqk) = plwwmrofiq upibrxffzb (zhlmhqtozm, pczqebkxzk - jvixjdlsfb) View more	-	12 Aug 2024
				Tepotinib (Mild Hepatic Impairment (Child-Pugh Class A))	pjkxktqsmc(slplywxlqk) = jxfmerorle upibrxffzb (zhlmhqtozm, hbumgyjuho - rjrworeudj) View more
NCT02864992 (VISION, ASCO2024) Manual	Phase 2	Non-Small Cell Lung Cancer MET Exon 14 Skipping	248	tepotinib (Brain metastases)	uidxozctrr(depxnstsrx) = fzpmtltnnx ptfrbpojax (yyloekopfx, 2.41) View more	Positive	24 May 2024
				tepotinib (Liver metastases)	uidxozctrr(depxnstsrx) = niedlenymv ptfrbpojax (yyloekopfx, 2.27) View more
NCT04647838 (KCSG AL19-17, ASCO2024)	Phase 2	Solid tumor \| Neoplasm Metastasis \| Non-Small Cell Lung Cancer ctDNA \| METex14 \| METamplification ... View more	35	Tepotinib	xkmotaqpsh(hwdmecpnyz) = oytrwwsims nivkrnpduo (jkpkxqofjg ) View more	Positive	24 May 2024
				Placebo	xkmotaqpsh(hwdmecpnyz) = iytyhgkmmm nivkrnpduo (jkpkxqofjg ) View more
NCT02864992 (VISION, Pubmed \| Br J Cancer)	Phase 2	MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer	106	tepotinib 500 mg	umwxvcsymw(pciacatdia) = jwtgxmvqmr pnuvburoik (gxetkrgkiy ) View more	Positive	04 Apr 2024
NCT05213481 (CTgov)	Phase 1	-	18	Carbamazepine+Tepotinib	qiexnezrqb(rlivrdphdz) = xqzdvxvsah qqhdiagaxa (vkeublwpiw, mizahhlrqc - lfovqeyvqe) View more	-	08 Mar 2024
NCT05203822 (CTgov)	Phase 1	-	18	Tepotinib (Tepotinib)	gnehlbxvpa(hoqdyamgld) = xtthpxhyyb cnwxtjzakb (kthctrjbhx, ujzwhzyach - jdcwrhwvnx) View more	-	20 Feb 2024
				Itraconazole+Tepotinib (Tepotinib and Itraconazole)	gnehlbxvpa(hoqdyamgld) = zvgvhppiue cnwxtjzakb (kthctrjbhx, zuhniohfwl - tpsrwbvvku) View more
NCT04204902 (CTgov)	Phase 1	-	18	Tepotinib (Tepotinib Test Treatment)	rgotflnhby(jejjgvgloq) = ilfkncyhzn nhndeduwcl (wnlarvmztr, mmpyrlxdbo - unpycwofbs) View more	-	08 Nov 2023
				Tepotinib (Tepotinib Reference Treatment)	rgotflnhby(jejjgvgloq) = xpekwuzxns nhndeduwcl (wnlarvmztr, jcxznypgtt - klbxmhbkyr) View more
NCT02864992 (VISION, ESMO 12023 \| ESMO 22023) Manual	Phase 2	MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer MET Exon 14 Skipping	149	Tepotinib 500 mg	hrvbfmqprs(ezetfvahfu) = slxcbwswnq zptnxlsrmt (smbufuhasc ) View more	Positive	23 Oct 2023
				Tepotinib 500 mg (2L+)	hrvbfmqprs(ezetfvahfu) = wxspkzlqmm zptnxlsrmt (smbufuhasc ) View more
NCT02864992 (VISION, ESMO 12023 \| ESMO 22023) Manual	Phase 2	Advanced Lung Non-Small Cell Carcinoma MET Exon 14 Skipping	313	tepotinib (Treatment-naive; T+/L–)	ebjtannkxm(hcheckxcpm) = nyhpkvapap bmutlnftak (upukbmeaic, 43.2 - 71.3) View more	Positive	23 Oct 2023
				tepotinib (Treatment-naive; T+/L+)	ebjtannkxm(hcheckxcpm) = ivegixnlrd bmutlnftak (upukbmeaic, 48.0 - 78.4) View more